Morning Buzz: Alcoa Inc. (AA), Twitter (TWTR), Apple (AAPL), Johnson & Johnson (JNJ)

Apple AAPL Store

Apple (AAPL) – The company confirmed on Friday the removal of ‘a few’ applications from its App Store over concerns they could compromise users’ security by putting in certificates that can expose data to monitoring third parties.

An Apple spokeswoman in a statement said, “Apple is deeply committed to protecting customer privacy and security. We are working closely with these developers to quickly get their apps back on the App Store, while ensuring customer privacy and security is not at risk.”

The U.S. technology giant did not state the precise number of apps at issue.

In other Apple news this morning: Apple’s mobile payments service, Apple Pay, will be accepted at Starbucks (SBUX) this year, while KFC and Chili’s will begin accepting Apple Pay sometime next year, according to Apple VP Jennifer Bailey.

Alcoa Inc. (AA) shares are down $0.39 to $10.62 in pre-market trading Friday after the company reported its third-quarter earnings results.

In its quarterly report, the aluminum maker said it earned $0.07 per share, well below the $0.14 per share analysts were expecting. Revenue fell approximately 11% year-over-year to $5.57 billion, below views for $5.67 billion. Net income for Q315 came in at $44 million, or $0.02 per share, compared to $149 million, or $0.12 per share, in third quarter 2014. The company said revenue was below forecasts due to lower aluminum prices.

AA currently prints a one year loss of about 31% and a year-to-date loss of around 30%.

Twitter, Inc. (TWTR) — At a conference held in New York yesterday the San Francisco-based company announced the addition of new capabilities to its video ad platform, allowing advertisers to more easily place short six-second ads – called pre-roll ads – that run before video chosen by users. Twitter will obviously split the revenue with publisher. The company however, did not say what its cut will be, but re/code pegs it at 30%.

Shares of Johnson & Johnson (JNJ) are up slightly this morning on news the New Brunswick, New Jersey-based medical products maker has begun a clinical trial of its experimental Ebola vaccine in Sierra Leone.

There is currently no licensed vaccine, treatment or cure for Ebola.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.